159691-25-5

Basic information

• Product Name: 4-(PYRROLIDIN-1-YLMETHYL)BENZOIC ACID
• Synonyms: 4-(PYRROLIDIN-1-YLMETHYL)BENZOIC ACID;AKOS BB-9432;4-(1-pyrrolidinylmethyl)benzoic acid(SALTDATA: HCl);4-(Pyrrolidin-1-ylMethyl)benzoic acid hydrochloride;4-(1-PyrrolidinylMethyl)-benzoic acid;4-(Pyrrolidin-1-ylmethyl)
• CAS NO: 159691-25-5
• Molecular Formula: C12H15NO2
• Molecular Weight: 205.25
• EINECS: 936-952-7
• Mol File: 159691-25-5.mol
• Article Data: 4

Chemical Properties

• Melting Point: 184 °C
• Boiling Point: 340.3°Cat760mmHg
• Flash Point: 159.6°C
• Appearance: /
• Density: 1.203g/cm³
• Vapor Pressure: 3.37E-05mmHg at 25°C
• Refractive Index: 1.596
• Storage Temp.: 2-8°C
• PKA: 4.03±0.10(Predicted)
• CAS DataBase Reference: 4-(PYRROLIDIN-1-YLMETHYL)BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(PYRROLIDIN-1-YLMETHYL)BENZOIC ACID(159691-25-5)
• EPA Substance Registry System: 4-(PYRROLIDIN-1-YLMETHYL)BENZOIC ACID(159691-25-5)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 159691-25-5(Hazardous Substances Data)

Usage

General Description

4-(Pyrrolidin-1-ylmethyl)benzoic acid is a chemical compound used in the pharmaceutical industry for its potential therapeutic applications. It is a derivative of benzoic acid, with a pyrrolidin-1-ylmethyl substituent attached to the benzene ring. 4-(PYRROLIDIN-1-YLMETHYL)BENZOIC ACID is a key intermediate in the synthesis of various pharmaceuticals, including antihypertensive and anti-inflammatory drugs. It has also been studied for its potential role in the treatment of neurological disorders and as a building block in the development of novel drug candidates. Additionally, 4-(pyrrolidin-1-ylmethyl)benzoic acid has shown promise as a chiral auxiliary in asymmetric synthesis, making it a valuable compound in medicinal chemistry research.

InChI:InChI=1/C12H15NO2/c14-12(15)11-5-3-10(4-6-11)9-13-7-1-2-8-13/h3-6H,1-2,7-9H2,(H,14,15)

Upstream product

• 52178-50-4 Methyl 3-formylbenzoate 
• 1571-08-0 methyl 4-formylbenzoate 
• 123-75-1 pyrrolidine 
• 1642-81-5 p-(chloromethyl)benzoic acid 

Relevant articles and documents

Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents

In present study, 4-anilinoquinazolines scaffold, arylurea and tertiary amine moiety were combined to design, synthesize gefitinib analogs and discover novel anticancer agents. A series of 4-anilinoquinazoline derivatives (1, 2, 3 and 4) bearing arylurea and tertiary amine moiety at its 6-position were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against A431 cell and A549 cell. The SAR of the title compounds was discussed. The compounds 2d, 2i and 2j with potent antiproliferative activities were evaluated their inhibitory activity against EGFR-TK. Compound 2j displayed potent inhibitory activity against EGFR-TK. In addition, compound 2j, at 50 mg/kg, can completely inhibit cancer growth in established nude mouse A549 xenograft model in vivo. These results suggest that the 4-anilinoquinazoline derivatives bearing diarylurea and tertiary amino moiety at its 6-position can serve as anticancer agents and EGFR inhibitors.

Permeability of novel 4′-N-substituted (aminomethyl) benzoate-7-substituted nicotinic acid ester derivatives of scutellarein in Caco-2 cells and in an in vitro model of the blood-brain barrier

A series of 4′-N-substituted (aminomethyl) benzoate-7-substituted nicotinic acid ester derivatives of scutellarein was designed and synthesized. Evaluation of physiochemical properties showed that the newly designed compounds had greater chemical stability and aqueous solubility than scutellarin or scutellarein. The permeabilities (Papp AP to BL) of compounds 7b and 7e in Caco-2 cells were 5.9-fold and 3.7-fold higher than that of scutellarin, and 3.7-fold and 2.4-fold higher than that of scutellarein. The permeabilities (Papp AP to BL) of compounds 7b and 7e in an in vitro model of the blood–brain barrier were 9.7-fold and 5.9-fold higher than that of scutellarin, and 9.2-fold and 5.6-fold higher than that of scutellarein.